Gladstone Institutional Advisory LLC Takes Position in Natera, Inc. (NASDAQ:NTRA)

Gladstone Institutional Advisory LLC purchased a new position in Natera, Inc. (NASDAQ:NTRA) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 3,568 shares of the medical research company’s stock, valued at approximately $453,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Wealth Enhancement Advisory Services LLC lifted its stake in shares of Natera by 25.0% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 5,776 shares of the medical research company’s stock valued at $528,000 after purchasing an additional 1,155 shares during the period. Sumitomo Mitsui Trust Holdings Inc. bought a new stake in shares of Natera during the 1st quarter valued at $33,956,000. Commonwealth Equity Services LLC purchased a new stake in shares of Natera in the 1st quarter worth about $1,392,000. FORA Capital LLC bought a new position in shares of Natera in the 1st quarter worth about $767,000. Finally, Jennison Associates LLC lifted its position in Natera by 121.9% during the 1st quarter. Jennison Associates LLC now owns 472,147 shares of the medical research company’s stock valued at $43,183,000 after acquiring an additional 259,336 shares during the period. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Natera

In other Natera news, CEO Steven Leonard Chapman sold 4,523 shares of the business’s stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $130.40, for a total transaction of $589,799.20. Following the completion of the sale, the chief executive officer now directly owns 191,163 shares in the company, valued at $24,927,655.20. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, insider Jonathan Sheena sold 12,000 shares of Natera stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $121.01, for a total transaction of $1,452,120.00. Following the transaction, the insider now directly owns 287,441 shares in the company, valued at approximately $34,783,235.41. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Steven Leonard Chapman sold 4,523 shares of the business’s stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $130.40, for a total value of $589,799.20. Following the sale, the chief executive officer now directly owns 191,163 shares of the company’s stock, valued at $24,927,655.20. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 50,164 shares of company stock valued at $6,157,291. 7.60% of the stock is owned by company insiders.

Natera Stock Up 2.6 %

Shares of Natera stock opened at $124.16 on Monday. Natera, Inc. has a twelve month low of $40.17 and a twelve month high of $133.54. The company has a quick ratio of 4.01, a current ratio of 4.14 and a debt-to-equity ratio of 0.34. The company’s 50 day moving average is $123.40 and its 200 day moving average is $112.38. The company has a market cap of $15.36 billion, a price-to-earnings ratio of -50.68 and a beta of 1.53.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Thursday, August 8th. The medical research company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.69) by $0.39. The firm had revenue of $413.35 million for the quarter, compared to analysts’ expectations of $343.00 million. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. The company’s revenue was up 58.1% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.97) EPS. Research analysts anticipate that Natera, Inc. will post -1.96 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on NTRA shares. BTIG Research raised their target price on shares of Natera from $125.00 to $135.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Robert W. Baird lifted their price objective on Natera from $117.00 to $120.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. StockNews.com downgraded Natera from a “hold” rating to a “sell” rating in a report on Friday, October 25th. Stephens restated an “overweight” rating and set a $125.00 price target on shares of Natera in a report on Friday, August 9th. Finally, Canaccord Genuity Group lifted their price target on Natera from $145.00 to $150.00 and gave the stock a “buy” rating in a research report on Tuesday, October 29th. One research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $125.69.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.